Published in final edited form as:

Ann Epidemiol. 2019 February ; 30: 9–14.e1. doi:10.1016/j.annepidem.2018.08.013.

Interleukin-10 as a predictor of major adverse cardiovascular events in a racially and ethnically diverse population: Multi-Ethnic Study of Atherosclerosis

Deena Goldwater, MD, PhD^{a,b}, Arun Karlamangla, MD, PhD^a, Sharon Stein Merkin, PhD^a, Karol Watson, MD, PhD^b, and Teresa Seeman, PhD^a

^aDepartment of Medicine, Division of Geriatrics, University of California, Los Angeles, 10945 Le Conte Ave, Ste 2339, Los Angeles, CA, 90095 (Deena Goldwater, Arun Karlamangla, Sharon Stein Merkin, Teresa Seeman)

^bDepartment of Medicine, Division of Cardiology, University of California, Los Angeles, 10833 Le Conte Ave, A2-237 Center for Health Sciences, Los Angeles, CA, 90095 (Deena Goldwater, Karol Watson)

Abstract

Purpose: To understand if baseline levels of the anti-inflammatory cytokine interleukin-10 (IL-10) are associated with either subclinical atherosclerosis or risk for adverse cardiovascular (CV) events.

Methods: The study included 930 adults from the Multi-Ethnic Study of Atherosclerosis (MESA) ancillary Stress Study. Participants, age 48–90 at enrollment, were followed for an average of 10.2 years. IL-10 level was measured at the initial Stress Study visit. Cardiovascular outcomes were defined as composite CV death, myocardial infarction, stroke, stroke death, and resuscitated cardiac arrest. Coronary calcification was determined by Agatston coronary artery calcium (CAC) score. The association between IL-10 level and CV event risk was evaluated by Cox proportional hazard modeling, while that of IL-10 level and CAC presence and amount was determined with prevalence risk ratio (PRR) and linear regression modeling, respectively. Models were adjusted for CV risk factors and pro-inflammatory biomarkers.

Results: After full adjustment, IL-10 level did not predict CV events (HR 1.19, 95%CI 0.89, 1.60), and was not associated with CAC prevalence (PRR 1.00, 95%CI 0.94, 1.07), nor amount of CAC in those with non-zero CAC (β -0.01, 95%CI -0.23, 0.21).

Conclusion: In individuals without clinical heart disease, baseline IL-10 level appears unrelated to risk of CV events and is a poor marker of subclinical coronary atherosclerosis.

Correspondence to: Deena Goldwater, dgoldwater@mednet.ucla.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Inflammation; cardiovascular diseases; coronary artery disease; interleukin-10

INTRODUCTION

Interleukin-10 (IL-10) is an anti-inflammatory cytokine thought to be protective against the development and progression of atherosclerosis. Secreted by macrophages, B cells, and T-helper cells in response to systemic inflammation, IL-10 suppresses antigen presenting capacity, dendritic cell activity, and T-cell proliferation, as well as negatively regulates pro-inflammatory cytokine production [1, 2]. With respect to cardiovascular (CV) disease, animal data suggest that IL-10 prevents atherosclerotic plaque development, [3, 4] improves plaque stability, [3] and promotes lesion size reduction [5].

Given the anti-inflammatory and anti-atherosclerotic properties of IL-10, higher levels would be expected to protect against CV disease and events. Indeed, data suggests that a higher level of IL-10 at the time of an acute coronary syndrome event is protective against risk for future cardiovascular events [6–8]. Yet, epidemiologic data do not consistently demonstrate this relationship. In clinically stable populations, preliminary evidence from two studies suggests that higher IL-10 concentrations relate to increased, as opposed to decreased, risk for adverse cardiovascular events [9, 10]. Importantly, these results may be condition specific, as the two cohorts were of 1) older adults [10] and 2) postmenopausal women with known cardiovascular disease [9]. A possible explanation for these counterintuitive findings is that IL-10, produced in response to circulating cytokines such as interleukin-6 (IL-6) and tumor necrosis factor α (TNF α) [11, 12], acts as a surrogate marker of an overall pro-inflammatory milieu. However, the relationship between pro- and antiinflammatory cytokines in individuals free of clinical heart disease, as well as the context in which steady-state IL-10 levels relate to cardiovascular disease development require further exploration.

Designed to explore the role of stress and inflammation in CV disease, the Multi-Ethnic Study of Atherosclerosis (MESA) Stress Study provides a unique opportunity to study IL-10 and its role in CV risk prediction. The Stress Study cohort is a community-dwelling, racially and ethnically diverse population from whom both traditional cardiovascular risk factors as well as a broader selection of inflammatory biomarkers were collected. Utilizing this robust dataset, we examined the relationship of IL-10 level to the overall inflammatory milieu, as well as the ability of IL-10 level to predict future adverse cardiovascular events and the prevalence and amount of coronary artery calcification (CAC). We hypothesized that IL-10 level is positively associated with pro-inflammatory biomarkers, and that higher a IL-10 level would increase risk for future CV events as well as be positively associated with prevalence and amount of coronary artery calcification.

METHODS

Study population

MESA is a prospective, longitudinal cohort study designed to understand risk factors related to the development and progression of CV disease and incident CV events. MESA recruited 6814 men and women age 45–84 free from overt CV disease at baseline from 6 communities including: Baltimore, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles, California; New York, New York; and St. Paul, Minnesota. Initial examination occurred between July 2000 and August 2002 with longitudinal follow up through July 2015. Detailed information regarding MESA study design and recruitment has been published previously [13]. The institutional review boards of all participating institutions approved the study protocols and consent procedures.

The data utilized in this study come from the MESA Stress Study, an ancillary study investigating the role of stress in cardiovascular disease. The Stress Study enrolled a cohort of 1002 MESA participants at either MESA visit 3 or visit 4 via the New York, NY, and Los Angeles, CA, field center between July 2004 and November 2006. About 500 individuals were enrolled at each site, resulting in a random sample at each site of black, Hispanic, and white participants. Of note, since the MESA New York field center did not enroll Asians, Stress Study enrollment was limited to white, black and Hispanic individuals. Beyond the standard MESA data collection, inflammatory biomarker data, including IL-6, TNF α , and IL-10, were collected from participants. Additional details of the Stress Study have been published previously [14–17].

Our objective was to explore the relationship between pro- and anti-inflammatory biomarkers in individuals free of clinical heart disease, as well as the relationship between IL-10 level, risk of future CV events, and CAC prevalence and amount. We therefore excluded 53 individuals with incomplete inflammatory biomarker profiles. We excluded an additional 19 individuals who experienced a cardiovascular event prior to inflammatory biomarker data collection, leaving a total initial sample of 930 participants.

Biomarker measurement

Most of the physiological and laboratory data used in the analyses were collected at the Stress Study visit as described previously [17]. Briefly, biomarkers including IL-10, IL-6, TNF α , and high sensitivity C-reactive protein (hsCRP), and were collected during a morning blood draw from fasting individuals. Cytokine assays were performed at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT). Concentrations of IL-6, IL-10, and TNF α were measured by enzyme-linked immunosorbent assay (Quantikine HS Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN), multiplex MAP human cardiovascular disease panel 3 (Millipore Corporation; Billerica, MA), and LINCoplex Human Cardiovascular Disease Panel 3 kit (Millipore Corporation, St. Charles, MO), respectively. The average analytical coefficient of variability for IL-6, IL-10, and TNF α , was 6.3%, 8.1%, and 10.3%, respectively. Levels of hsCRP were only available from MESA visit 1. Despite the temporal discordance, this biomarker was incorporated into the analysis given the previously described relationship between elevated

hsCRP and the risk for cardiovascular disease [18]. The level of hsCRP was measured using immunonephelometry (N hsCRP; Dade Behring Inc, Deerfield, IL, USA) with an interassay coefficient of variability of 5.7% [19]. The time between hsCRP measurement and the Stress Study visit was measured in years.

Additional Covariates

Additional covariates were determined from Stress Study visit data. Data includes age, gender, race/ethnicity (white, black, or Hispanic), body mass index (BMI), systolic blood pressure (SBP), total cholesterol, high-density lipoprotein cholesterol (HDL), aspirin use, statin use, antihypertensive medication use, diabetes (present or absent), and smoking status (never, prior, or current smoker). Resting blood pressure was measured using the automated oscillometric method (Dinamap). Three measurements were obtained while individuals were in the seated position; the average of the last two measures were used for analyses. Fasting total cholesterol (TC) and HDL were measured in plasma using a cholesterol esterase, cholesterol oxidase reaction (Chol R1, Roche Diagnostics) in individuals who had fasted 10 hours. Diabetes status was determined according to the American Diabetes Association definition of fasting glucose > 126 mg/dL or a history of medical management of diabetes[20]. Smoking status, current aspirin use, current statin use, and current antihypertensive medication use were determined by self-report.

Outcomes

CV events

Cardiovascular events were defined as time to first CV event, which was a composite outcome of cardiovascular death, myocardial infarction, and stroke, stroke death, and resuscitated cardiac arrest. Events were identified by participant self-report as well as review and abstraction of medical records, including death certificates. Events were adjudicated by at least two physicians, with differences of opinion resolved by committee review. Data on incident CV events is available through the follow-up end date of December 31, 2015. Follow-up time was measured from the date of the MESA Stress exam (corresponding to either MESA visit 3 or 4) up to the date of the first CV event (for those who experienced an event) or last date of follow up.

Coronary artery calcium measurement

MESA participants underwent two coronary artery computed tomography (CT) scans to assess coronary artery calcification, as described previously [21]. The initial scan for each participant occurred during MESA visit 1. Each participant had one follow-up coronary artery CT scan that occurred either at MESA visit 2 or visit 3. For this study, the Agatston CAC score obtained closest to the participant's Stress Study visit (either visit 3 or 4) was used. In individuals with non-zero CAC, the log-transformed Agatston score was used as a measure of total amount of coronary calcification. The time between coronary artery CT and Stress study visit was measured in years.

Analysis

All inflammatory biomarkers were winsorized at the 1st and 99th percentile and then log-transformed prior to parametric analysis. Pearson correlation analyses between inflammatory biomarkers IL-10, IL-6, TNF α , and hsCRP and Spearman correlation analyses between IL-10 and patient characteristics were performed. KaplanMeier time-to-event analysis of the unadjusted association between IL-10 levels and time to major adverse cardiovascular events were performed; estimates were compared using the log-rank test. The association between IL-10 level and CV event risk was evaluated by Cox proportional hazard modeling. Three models were used: Model 1 was unadjusted; Model 2 was adjusted for pro-inflammatory biomarkers IL-6, TNF α , and hsCRP; Model 3 was adjusted for pro-inflammatory biomarkers as well as common CV risk factors including age, gender, race/ethnicity, BMI, SBP, TC, HDL cholesterol, aspirin use, statin use, any antihypertensive medication use, diabetes status, and smoking status. Additional regression models were fit to determine the association between IL-10 level and CAC. Given that the frequency of CAC = 0 versus CAC > 0 is near 50% in the MESA population [22], prevalence risk ratio (PRR) regression modeling was utilized in favor of logistic regression to determine the relationship between IL-10 level and the presence or absence of CAC. Prevalence risk ratio regression assumed Gaussian error and used robust standard error estimates. In individuals with non-zero CAC, linear regression models were fit to evaluate the relationship between IL-10 level and amount of CAC. Three models were used: Model 1 was adjusted for time from coronary CT scan to Stress Study visit; Model 2 was adjusted for time from coronary CT to Stress Study visit as well as pro-inflammatory biomarkers IL-6, TNF α , and hsCRP; Model 3 was adjusted for time from coronary CT to Stress Study visit, pro-inflammatory biomarkers, and the common CV risk factors of age, gender, race/ethnicity, BMI, SBP, total cholesterol, HDL cholesterol, aspirin use, statin use, any antihypertensive medication use, diabetes status, and smoking status.

RESULTS:

Baseline characteristics and summary statistics for inflammatory biomarkers of the 930 individuals from the MESA Stress Study are provided in Table 1. The average follow-up time was 10.2 years (± 2.6) and the number of major adverse CV events was 83 (8.9%). We found that the level of the anti-inflammatory cytokine IL-10 is weakly correlated with levels of pro-inflammatory biomarkers IL-6 ($r = 0.086$, $p < 0.01$) and TNF α ($r = 0.097$, $p < 0.01$) and has no correlation with hsCRP (Table 2). Kaplan-Meier time-to-event analysis of unadjusted associations between IL-10 levels and time to major adverse cardiovascular event demonstrated no significant differences between IL-10 level quartiles and outcomes (Figure 1). In the unadjusted Cox proportional hazard models, one SD increase in log IL-10 concentration showed a trend toward association with major adverse CV events (HR 1.26, 95% CI 0.97–1.65; $p = 0.09$) (Table 3). After adjusting for pro-inflammatory biomarkers, as well as other covariates known to influence CV risk, the hazard ratio was not statistically significant (HR 1.19; CI 0.89–1.60; $p = 0.24$) (Table 3). With respect to CAC, in all models, IL-10 level was not related to the estimated prevalence risk for CAC nor was IL-10 level associated with total amount of CAC in individuals with non-zero CAC (Table 4). Of note, despite the lack of significance with respect to IL-10, the pro-inflammatory biomarkers

demonstrated significant association with major adverse CV events and CAC. In Cox proportional hazard modeling, IL-6 level was significantly associated with adverse CV events in Model 2 (HR 1.70, 95% CI 1.16–2.49; $p < 0.01$), although this relationship did not remain significant in the fully adjusted Model 3 (data not shown). Moreover, IL-6 (Model 2: PRR 1.2, 95% CI 1.08–1.33, $p < 0.001$) and TNF α (Model 2: PRR 1.19, 95% CI 1.11–1.29, $p < 0.0001$; Model 3: PRR 1.12, 95% CI 1.05–1.20, $p < 0.001$) levels were positively associated with the presence of CAC (data not tabulated), while IL-6 level was also positively associated with the amount of CAC in Model 2 (β 0.43; 95% CI 0.12–0.74, $p < 0.01$), although not in the fully adjusted model (data not tabulated).

DISCUSSION:

In this prospective, longitudinal study of a racially and ethnically diverse population, we set out to characterize the relationship between pro- and anti-inflammatory cytokines, as well as confirm the association between the anti-inflammatory cytokine IL-10 and risk for major adverse cardiovascular events. We confirmed the hypothesis that IL-10 level is positively correlated with the levels of some pro-inflammatory biomarkers, albeit weakly. However, we were unable to confirm a relationship between IL-10 level and risk for future major adverse cardiovascular events, presence or absence of coronary calcification, nor the total amount of coronary calcification.

The relationship between circulating pro- and anti-inflammatory cytokines remains incompletely characterized. Data suggests that IL-10 level increases simultaneously with other inflammatory cytokines, including IL-6 and TNF α , during an acute coronary event [23, 24], leading to the hypothesis that IL-10 is a surrogate marker of the overall inflammatory milieu. Although we found levels of IL-6 and TNF α to be positively related to IL-10, the association was weak. Moreover, with the exception of gender, total cholesterol, and HDL cholesterol, we were unable to find a significant association between IL-10 concentration and other patient characteristics that may influence inflammation such as obesity, diabetes, statin or aspirin use, or smoking status (Supplementary Table 1). Therefore, although IL-10 level may represent a surrogate marker of the overall inflammatory milieu during an acute event, we were unable to confirm a strong relationship in a population without clinically significant cardiac disease at baseline. The interrelation between IL-10 level and the steady-state inflammatory milieu requires further investigation.

Evidence from epidemiologic studies suggest that the predictive ability of IL-10 for fatal and nonfatal cardiovascular events is highly context dependent. The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) cohort was composed of older men and women (age 70–82) from Scotland, Ireland, and the Netherlands [10]. In this large group of close to 6000 individuals, baseline levels of IL-10 were associated with a slightly increased risk for adverse events, a finding that was specific to individuals *without* preexisting vascular disease [10]. On the other hand, in the much smaller Estrogen Replacement and Atherosclerosis (ERA) Study of 309 postmenopausal women, IL-10 concentration was positively correlated with adverse outcomes in women *with* coronary artery disease [9]. Taken together, these data potentially support a role for IL-10 as a risk predictor in distinct population subsets. In this study, we investigated whether risk associated with IL-10

elevation could be more broadly applied to a contemporary, diverse, community-dwelling population without clinically significant cardiovascular disease at baseline. Contrary to the previous studies, we do not find a relationship between IL-10 level and adverse cardiovascular events (Table 4). The wide variability between cohorts with respect to age, racial/ethnic, and gender differences likely contributes to the lack of consistent findings. Although IL-10 may be a useful biomarker within specific populations, its utility for cardiovascular risk prediction in the general population remains questionable.

Small studies suggest that higher levels of IL-10 are associated with lower coronary artery atherosclerotic burden [25–27] and more plaque stability [28], leading to the hypothesis that IL-10 may slow atherosclerotic disease development and progression. However, we did not find a relationship between IL-10 level and the presence or absence of CAC. Additionally, we confirm a previous finding that steady-state levels of IL-10 are not associated with total coronary calcification amount [29]. Although IL-10 may impact atherosclerosis in a local vascular-bed environment, systemic levels of IL-10 appear unrelated to coronary artery disease severity.

This study has a number of potential limitations. The first concern is that only a small number of pro-inflammatory cytokines were utilized to determine the overall inflammatory environment. Indeed, it is likely that some components of inflammation were not captured by the available biomarkers. However, the weak relationship between IL-10 level and the pro-inflammatory markers is consistent with findings in other studies of clinically stable populations [10]. Moreover, the data presented here that pro-inflammatory biomarkers are associated with adverse CV outcomes and coronary calcification suggests that the inflammation captured in this cohort is similar to previous studies [30–34]. The second limitation is the variable amount of time between coronary CT and the Stress Study visit. To minimize the impact of this temporal discrepancy, the results presented here adjust for the time between imaging and biomarker measurement when appropriate. Finally, the small number of cardiovascular events observed in the MESA Stress Study precluded age- and race/ethnicity-stratified analyses to look for group specific associations between IL-10, CV events, and presence of coronary artery disease. Future analysis may be undertaken once more events have accumulated in this population.

In conclusion, in this racially and ethnically diverse population of individuals free of clinical heart disease at baseline, we were able to demonstrate a weak association between circulating levels of IL-10 with pro-inflammatory cytokines. However, we were unable to confirm previous reports that the steady-state IL-10 concentration relates to risk for future CVD events, nor is it associated with the presence or amount of coronary calcification. Although the anti-inflammatory properties of IL-10 with respect to CV disease are intriguing, consistent results in large epidemiologic studies implicating IL-10 in risk prediction remain elusive. Additional work aimed at understanding the complexity of cytokine interrelationships, as well as the molecular mechanisms with which IL-10 affects plaque architecture and stability, may help with future studies. However, at this time, the utility of IL-10 in clinical risk prediction models remains limited.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The analysis of the data presented herein was supported by the UCLA Older American Independence Center (OAIC) NIH/NIA P30 AG028748. Additionally, support for the larger MESA study was provided by contracts from the National Heart, Lung, and Blood Institute [HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169] and by grants from the National Center for Advancing Translational Sciences [UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420]. The authors would like to acknowledge the valuable contribution of the investigators, staff, and participants of the MESA study. A full list of participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org>.

List of abbreviations:

BMI	body mass index
CAC	coronary artery calcium
CT	computed tomography
CV	cardiovascular
HDL	high-density lipoprotein
HR	hazard ratio
hsCRP	high sensitivity C-reactive protein
IL-6	interleukin-6
IL-10	interleukin-10
MESA	Multi-Ethnic Study of Atherosclerosis
PRR	prevalence risk ratio
TC	total cholesterol
TNFα	tumor necrosis factor- α

References

- [1]. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. *Immunological reviews* 2008;223:114–31. [PubMed: 18613832]
- [2]. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. *Nature reviews Immunology* 2010;10(3):170–81.
- [3]. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. *Molecular medicine* 2003;9(1–2):10–7. [PubMed: 12765335]
- [4]. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2010;24(8):2869–80. [PubMed: 20354139]

- [5]. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. *Circulation research* 2002;90(10):1064–71. [PubMed: 12039795]
- [6]. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. *Circulation* 2003;107(16):2109–14. [PubMed: 12668510]
- [7]. Zhang DF, Song XT, Chen YD, Yuan F, Xu F, Zhang M, et al. Prognostic performance of interleukin-10 in patients with chest pain and mild to moderate coronary artery lesions-an 8-year follow-up study. *Journal of geriatric cardiology : JGC* 2016;13(3):244–51. [PubMed: 27103920]
- [8]. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marin JL, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. *American heart journal* 2002;144(5):811–7. [PubMed: 12422149]
- [9]. Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. *Atherosclerosis* 2008;197(1):443–7. [PubMed: 17706223]
- [10]. Welsh P, Murray HM, Ford I, Trompet S, de Craen AJ, Jukema JW, et al. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. *Arteriosclerosis, thrombosis, and vascular biology* 2011;31(10):2338–44.
- [11]. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nature immunology* 2007;8(12):1363–71. [PubMed: 17994025]
- [12]. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor- α in human monocyte IL10 synthesis. *Journal of immunology* 1993;151(12):6853–61.
- [13]. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. *American journal of epidemiology* 2002;156(9):871–81. [PubMed: 12397006]
- [14]. Diez Roux AV, Ranjit N, Jenny NS, Shea S, Cushman M, Fitzpatrick A, et al. Race/ethnicity and telomere length in the Multi-Ethnic Study of Atherosclerosis. *Aging cell* 2009;8(3):251–7. [PubMed: 19302371]
- [15]. Do DP, Diez Roux AV, Hajat A, Auchincloss AH, Merkin SS, Ranjit N, et al. Circadian rhythm of cortisol and neighborhood characteristics in a population-based sample: the Multi-Ethnic Study of Atherosclerosis. *Health & place* 2011;17(2):625–32. [PubMed: 21292535]
- [16]. Hajat A, Diez-Roux A, Franklin TG, Seeman T, Shrager S, Ranjit N, et al. Socioeconomic and race/ethnic differences in daily salivary cortisol profiles: the multi-ethnic study of atherosclerosis. *Psychoneuroendocrinology* 2010;35(6):932–43. [PubMed: 20116177]
- [17]. DeSantis AS, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS, et al. Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology* 2012;37(7):1009–18. [PubMed: 22178583]
- [18]. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375(9709):132–40. [PubMed: 20031199]
- [19]. DeGoma EM, French B, Dunbar RL, Allison MA, Mohler ER, 3rd, Budoff MJ. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2012;224(1):274–9. [PubMed: 22846611]
- [20]. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes care* 2003;26(11):3160–7. [PubMed: 14578255]
- [21]. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, Jr, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. *Radiology* 2005;234(1):35–43. [PubMed: 15618373]

- [22]. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation* 2006;113(1):30–7. [PubMed: 16365194]
- [23]. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-Maj E, et al. Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. *Coronary artery disease* 2003;14(6):431–8. [PubMed: 12966263]
- [24]. Rajappa M, Sen SK, Sharma A. Role of pro-/anti-inflammatory cytokines and their correlation with established risk factors in South Indians with coronary artery disease. *Angiology* 2009;60(4):419–26. [PubMed: 18796448]
- [25]. Freitas WM, Quaglia LA, Santos SN, Soares AA, Japiassu AV, Boaventura V, et al. Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. *Atherosclerosis* 2011;216(1):212–6. [PubMed: 21316055]
- [26]. Jha HC, Divya A, Prasad J, Mittal A. Plasma circulatory markers in male and female patients with coronary artery disease. *Heart & lung : the journal of critical care* 2010;39(4):296–303. [PubMed: 20561855]
- [27]. Mirhafez SR, Zarifian A, Ebrahimi M, Ali RF, Avan A, Tajfard M, et al. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. *Clinical biochemistry* 2015;48(9):575–80. [PubMed: 25712751]
- [28]. George J, Schwartzberg S, Medvedovsky D, Jonas M, Charach G, Afek A, et al. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. *Atherosclerosis* 2012;222(2):519–23. [PubMed: 22575708]
- [29]. Gauss S, Klinghammer L, Steinhoff A, Raaz-Schrauder D, Marwan M, Achenbach S, et al. Association of systemic inflammation with epicardial fat and coronary artery calcification. *Inflammation research : official journal of the European Histamine Research Society [et al.]* 2015;64(5):313–9.
- [30]. Weiner SD, Ahmed HN, Jin Z, Cushman M, Herrington DM, Nelson JC, et al. Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). *Heart* 2014;100(11):862–6. [PubMed: 24714919]
- [31]. Raaz-Schrauder D, Klinghammer L, Baum C, Frank T, Lewczuk P, Achenbach S, et al. Association of systemic inflammation markers with the presence and extent of coronary artery calcification. *Cytokine* 2012;57(2):251–7. [PubMed: 22172511]
- [32]. Harada K, Amano T, Uetani T, Yoshida T, Kato B, Kato M, et al. Association of inflammatory markers with the morphology and extent of coronary plaque as evaluated by 64-slice multidetector computed tomography in patients with stable coronary artery disease. *The international journal of cardiovascular imaging* 2013;29(5):1149–58. [PubMed: 23358918]
- [33]. Ramadan MM, Mahfouz EM, Gomaa GF, El-Diasty TA, Alldawi L, Ikrar T, et al. Evaluation of coronary calcium score by multidetector computed tomography in relation to endothelial function and inflammatory markers in asymptomatic individuals. *Circulation journal : official journal of the Japanese Circulation Society* 2008;72(5):778–85. [PubMed: 18441459]
- [34]. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. *PLoS medicine* 2008;5(4):e78. [PubMed: 18399716]

Figure 1 –.

Time to major adverse cardiovascular event by IL-10 level. IL-10 levels are grouped from lowest (quartile 1) to highest (quartile 4). There is no significant difference between IL-10 level quartiles and outcome ($p = 0.2$).

Table 1:

Baseline characteristics of MESA Stress ancillary study cohort

Variable (N = 930)	N (%) or mean (SD)
Age [range 48–90]	65 (9.8)
Men	434 (47%)
Race/ethnicity	
White	179 (19%)
Black	267 (29%)
Hispanic	484 (52%)
BMI (kg/m ²)	29 (5.7)
Diabetic	162 (17%)
Smoking status	
Never	429 (46.4%)
Former	310 (33.6%)
Current	183 (20.0%)
Systolic blood pressure (mmHg)	123.3 (20.4)
Total cholesterol (mg/dl)	190.8 (38.1)
HDL cholesterol (mg/dl)	51.4 (15.1)
Medication use	
Aspirin at least 3 days per week	272 (29%)
Statin	203 (22%)
Any antihypertensive medication	426 (46.8%)
Follow-up time (years)	10.2 (2.6)
Incidence of major adverse CVD events	83 (8.9%)
Coronary Calcification (Agatston) [*]	
CAC = 0	453 (48.7%)
CAC < 100	270 (29.0%)
CAC > 100	207 (22.3%)
Time between Coronary CT and Stress Study visit (years)	1.5 (1.2)
Inflammatory markers	
IL-10 (pg/ml)	7.98 (13.34)
IL-6 (pg/ml)	2.83 (1.94)
TNFα (pg/ml)	4.32 (5.74)
hsCRP (mg/L) [†]	3.85 (5.20)

BMI = Body mass index; HDL = high density lipoprotein cholesterol; CAC = coronary artery calcium; IL-10 = Interleukin 10; IL-6 = interleukin-6; TNFα = tumor necrosis factor α; hsCRP = high sensitivity C-reactive protein;

^{*} Agatston coronary artery calcium (CAC) score obtained closest to the Stress Study visit

[†] The average time between hsCRP measurement (MESA visit 1) to other inflammatory biomarker measurement (Stress Study visit) was 3.86 ± 0.9 years.

Table 2:

Correlation between IL-10 and pro-inflammatory biomarker levels

	IL-6	TNFα	hsCRP
IL-10	0.086 [†]	0.097 [†]	-0.009

Data presented as Pearson correlation coefficients. Biomarkers were log transformed prior to analysis;

[†]_p 0.01

IL-10 = Interleukin-10; IL-6 = interleukin-6, TNF α = tumor necrosis factor α ; hsCRP = high sensitivity C reactive protein

Table 3:

Cox proportional hazard models of adverse CV events by IL-10 level

	Hazard ratio* (95% CI)	P
Model 1 (N=930)	1.26 (0.97–1.65)	0.09
Model 2 (N = 930)	1.21 (0.92–1.58)	0.17
Model 3 (N = 901)	1.19 (0.89–1.60)	0.24

* Hazard ratio of adverse CV event by SD change in log-transformed IL-10 level

Model 1 – Unadjusted model

Model 2 – Adjusted for pro-inflammatory biomarkers IL-6, TNF α , and hsCRP

Model 3 – Adjusted for pro-inflammatory biomarkers with additional adjustment for age, gender, race/ethnicity, BMI, total cholesterol, HDL, smoking status, diabetes status, aspirin use, statin use, and any antihypertensive medication use.

All biomarkers were log transformed prior to analysis

IL-10 = Interleukin-10; SD = standard deviation; CI = confidence interval

Table 4:

Association of IL-10 levels with prevalence and amount of coronary artery calcification

		Prevalence risk ratio of CAC* (95% CI)	<i>p</i>
IL-10 association with prevalence of CAC	Model 1 (N = 930)	1.06 (0.97–1.14)	0.16
	Model 2 (N = 930)	1.02 (0.94–1.10)	0.65
	Model 3 (N = 909)	0.99 (0.93–1.06)	0.88
		Mean difference in CAC [†] (95% CI)	<i>p</i>
IL-10 association with amount of CAC in individuals with CAC > 0	Model 1 (N = 477)	0.01 (–0.06–0.35)	0.93
	Model 2 (N = 477)	–0.05 (–0.25–0.22)	0.89
	Model 3 (N = 462)	–0.01 (–0.23–0.21)	0.94

* Prevalence risk ratio of CAC by SD increase in log-transformed IL-10 level

[†] Mean difference in log-transformed Agatston score by SD increase in log-transformed IL-10 level

Model 1 – Adjusted for time between CAC measurement and Stress Study visit

Model 2 – Adjusted for time between CAC measurement and Stress Study visit as well as for proinflammatory biomarkers IL6, TNFα, and hsCRP

Model 3 – Adjusted for time between CAC measurement and Stress Study visit and pro-inflammatory biomarkers with additional adjustment for age, gender, race/ethnicity, BMI, total cholesterol, HDL, smoking status, diabetes status, aspirin use, statin use, and any antihypertensive medication use. All biomarkers were log-transformed prior to analyses

Agatston score was log-transformed prior to analyses

IL-10 = Interleukin-10; CAC = coronary artery calcification; SD = standard deviation; CI = confidence interval